Zobrazeno 1 - 10
of 241
pro vyhledávání: '"Manfred, Welslau"'
Autor:
Meinolf Karthaus, Volker Heinemann, Jorge Riera-Knorrenschild, Albrecht Kretzschmar, Manfred Welslau, Ulrich Kaiser, Henning Pelz, Thomas J. Ettrich, Swantje Held, Linde Kehmann, Jürgen Hess, Timo Reisländer, Lena Weiss, on behalf of the TALLISUR study group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background In the pivotal phase III RECOURSE trial, trifluridine/tipiracil (FTD/TPI) improved progression-free and overall survival (PFS, OS) of patients with pre-treated metastatic colorectal cancer (mCRC). Subsequently, the TALLISUR trial
Externí odkaz:
https://doaj.org/article/bfc837e7c22d4f35917763b74a09a350
Autor:
Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, Kamel Laribi
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 45-54 (2023)
Abstract The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in p
Externí odkaz:
https://doaj.org/article/fe50306f84f445cd873e4e8c3079f682
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: REFLECT is the first prospective study of Sandoz biosimilar rituximab (SDZ-RTX) in patients with diffuse large B-cell lymphoma (DLBCL). Objective: To evaluate the 2-year effectiveness and safety of SDZ-RTX as first-line treatment for DLBC
Externí odkaz:
https://doaj.org/article/737e11320d6c4d6394455a146a309f77
Autor:
Manuela Eicher, Sanna Iivanainen, Maria Reig, Amparo Yovanna Castro Sanchez, Anne-Marie Baird, Bogdana Balas, Alberto Bustillos, Sophie Golding, Mathis Mueller-Ohldach, Manfred Welslau, Johannes Ammann
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Introduction Digital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad adoption requires ease of use and demonstration of real-world clinical utility/impact. ORIGAMA (
Externí odkaz:
https://doaj.org/article/d84f45f54c0149dcaaf9cd6c718b2e56
Autor:
Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 8127-8137 (2021)
Abstract Background Platinum‐based chemotherapy remains a first‐line standard of care for approximately 30% of patients with non‐small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab‐pac
Externí odkaz:
https://doaj.org/article/5b6b2c18b24b4eb19418ef882658d450
Autor:
Andreas Jakob, Mark-Oliver Zahn, Arnd Nusch, Thorsten Werner, Roland Schnell, Melanie Frank, Nicole Hamm, Klaus-Ulrich Däßler, Christoph Losem, Manfred Welslau, Petra Hoevel, Karin Potthoff
Publikováno v:
Journal of Bone Oncology, Vol 33, Iss , Pp 100420- (2022)
Background: In breast cancer and prostate cancer patients, bone metastases (BM) present the main cause of morbidity and often cause debilitating pain, impaired functioning and subsequent deterioration of quality of life (QoL). The management of BM is
Externí odkaz:
https://doaj.org/article/838f29e13cf24c1c9959f432e75b8d4d
Autor:
Markus Hecht, Dennis Hahn, Philipp Wolber, Matthias G. Hautmann, Dietmar Reichert, Steffi Weniger, Claus Belka, Tobias Bergmann, Thomas Göhler, Manfred Welslau, Christina Große-Thie, Orlando Guntinas-Lichius, Jens von der Grün, Panagiotis Balermpas, Katrin Orlowski, Diethelm Messinger, Karsten G. Stenzel, Rainer Fietkau
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Head and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response with patient reported tumor s
Externí odkaz:
https://doaj.org/article/b0e785e23cee4e3ebc4a8def0086024d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Ursula Oppermann, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff
Publikováno v:
International Journal of Cancer. 153:141-152
Autor:
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20:43-56
Zusammenfassung Hintergrund Umfangreiche Daten aus prospektiven klinischen Studien liefern einen hohen Evidenzgrad für den Einsatz von CDK4/6-Hemmern in Kombination mit einer endokrinen Therapie (CDK4/6i + ET) als Standard bei der First-Line-Behandl